Outlook Therapeutics grants stock options and FDA-contingent cash bonuses to CEO and CFO

Outlook Therapeutics, Inc.

CEO Robert C. Jahr granted 100,000 stock options at $1.4304/share, vesting July 21, 2027.
CFO Lawrence A. Kenyon granted 210,078 stock options at same price and vesting schedule.
Cash bonuses of $420,000 (Jahr) and $200,000 (Kenyon) contingent on FDA approval of ONS-5010 by July 31, 2026.
Bonuses awarded for 2025 service contributions and BLA advancement; no 2025 annual bonuses paid.
Options and bonuses approved by Compensation Committee on July 21, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.